MedTrace Logo

Impact of Combined Intravenous-Inhalational vs Inhalational Anesthesia on QoR-15 Recovery Scores in Gynecologic Surgery

NCT07506798 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-04-02

No results posted yet for this study

Summary

This study aims to compare the effects of combined intravenous-inhalational anesthesia versus inhalational anesthesia alone on postoperative recovery in patients undergoing elective gynecologic surgery.

A total of 100 patients, aged 18-65 years and classified as ASA I-III, scheduled for elective gynecologic procedures at Sakarya University Faculty of Medicine Training and Research Hospital, will be included. The sample size was calculated based on the primary outcome, the Quality of Recovery-15 (QoR-15) score.

Patients will complete the QoR-15 questionnaire preoperatively, before knowing which anesthesia method will be applied. Postoperative QoR-15 scores will be collected on postoperative days 1 and 2, and intraoperative data will be obtained from anesthesia records.

The study evaluates postoperative recovery using QoR-15 scores, covering physical comfort, emotional state, psychological support, pain, and ability to perform daily activities. Higher scores indicate better recovery, whereas lower scores indicate impaired postoperative recovery.

Conditions

  • Gynecologic Surgery
  • Postoperative Recovery
  • Anesthesia

Interventions

DRUG

Combined Intravenous-Inhalational Anesthesia

Patients will receive a combination of intravenous anesthetic agents and inhalational anesthetic gases during elective gynecologic surgery. The specific anesthetic drugs and doses will follow routine clinical practice. Postoperative recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire on postoperative days 1 and 2.

DRUG

Inhalational Anesthesia Only

Patients will receive only inhalational anesthetic gases during elective gynecologic surgery, following routine clinical practice. Postoperative recovery will be assessed using the QoR-15 questionnaire on postoperative days 1 and 2.

Sponsors & Collaborators

  • Sakarya University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2027-04-30
Completion
2027-04-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07506798 on ClinicalTrials.gov